[The Significance of Bone Marrow Immature Plasma Cell Burden in the Prognosis of Newly Diagnosed Multiple Myeloma Patients]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2022 Mar 1

PMID 35231997

Authors

Y L Li

J Shi

F Z Liu

X Y Dong

C Y Wu

W Cheng

Z F Huang

Z M Zhu

Affiliations

Soon will be listed here.

References

Rajkumar S, Fonseca R, Lacy M, Witzig T, Therneau T, Kyle R . Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma. J Clin Oncol. 1999; 17(5):1551-7. DOI: 10.1200/JCO.1999.17.5.1551. View

Boyd K, Ross F, Chiecchio L, Dagrada G, Konn Z, Tapper W . A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial. Leukemia. 2011; 26(2):349-55. PMC: 4545515. DOI: 10.1038/leu.2011.204. View

Leung-Hagesteijn C, Erdmann N, Cheung G, Keats J, Stewart A, Reece D . Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013; 24(3):289-304. PMC: 4118579. DOI: 10.1016/j.ccr.2013.08.009. View

Wajs J, Sawicki W . The morphology of myeloma cells changes with progression of the disease. Contemp Oncol (Pozn). 2014; 17(3):272-5. PMC: 3934067. DOI: 10.5114/wo.2013.35282. View

Avet-Loiseau H, Durie B, Cavo M, Attal M, Gutierrez N, Haessler J . Combining fluorescent in situ hybridization data with ISS staging improves risk assessment in myeloma: an International Myeloma Working Group collaborative project. Leukemia. 2012; 27(3):711-7. PMC: 3972006. DOI: 10.1038/leu.2012.282. View

Kuroda Y, Sakai A, Okikawa Y, Munemasa S, Katayama Y, Hyodo H . The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agents. Int J Hematol. 2005; 81(4):335-41. DOI: 10.1532/IJH97.04189. View

Greipp P, Raymond N, Kyle R, OFallon W . Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood. 1985; 65(2):305-10. View

Shah V, Sherborne A, Walker B, Johnson D, Boyle E, Ellis S . Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients. Leukemia. 2017; 32(1):102-110. PMC: 5590713. DOI: 10.1038/leu.2017.179. View

Al-Sahmani M, Trnavska I, Sevcikova S, Antosova M, Antosova L, Kissova J . Prognostic significance of morphological assessment of plasma cells in multiple myeloma. Neoplasma. 2011; 58(6):554-60. DOI: 10.4149/neo_2011_06_554. View

10.

Iriyama N, Miura K, Hatta Y, Uchino Y, Kurita D, Takahashi H . Plasma cell maturity as a predictor of prognosis in multiple myeloma. Med Oncol. 2016; 33(8):87. DOI: 10.1007/s12032-016-0803-3. View

11.

Schmidt T, Barwick B, Joseph N, Heffner L, Hofmeister C, Bernal L . Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer J. 2019; 9(12):94. PMC: 6877577. DOI: 10.1038/s41408-019-0254-0. View

12.

Seili-Bekafigo I, Valkovic T, Babarovic E, Duletic-Nacinovic A, Jonjic N . Myeloma cell morphology and morphometry in correlation with clinical stages and survival. Diagn Cytopathol. 2013; 41(11):947-54. DOI: 10.1002/dc.22986. View

13.

Murakami H, Nemoto K, Sawamura M, Tamura J, Matsushima T, Naruse T . Prognostic relevance of morphological classification in multiple myeloma. Acta Haematol. 1992; 87(3):113-7. DOI: 10.1159/000204735. View

14.

Kishimoto R, de Freitas S, Ratis C, Borri D, Sitnik R, Velloso E . Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells. Rev Bras Hematol Hemoter. 2016; 38(2):113-20. PMC: 4877610. DOI: 10.1016/j.bjhh.2016.01.005. View

15.

Avet-Loiseau H, Attal M, Campion L, Caillot D, Hulin C, Marit G . Long-term analysis of the IFM 99 trials for myeloma: cytogenetic abnormalities [t(4;14), del(17p), 1q gains] play a major role in defining long-term survival. J Clin Oncol. 2012; 30(16):1949-52. DOI: 10.1200/JCO.2011.36.5726. View

16.

Greipp P, Leong T, Bennett J, Gaillard J, Klein B, Stewart J . Plasmablastic morphology--an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG Myeloma Laboratory Group. Blood. 1998; 91(7):2501-7. View

17.

Palta A, Kaur M, Tahlan A, Dimri K . Evaluation of Angiogenesis in Multiple Myeloma by VEGF Immunoexpression and Microvessel Density. J Lab Physicians. 2020; 12(1):38-43. PMC: 7419170. DOI: 10.1055/s-0040-1714933. View

18.

Takakuwa T, Araki T, Nakamura K, Fukuyama T, Miura A, Fujitani Y . Morphologic Classification Is an Important Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib or Lenalidomide. Ann Clin Lab Sci. 2020; 50(3):333-341. View

19.

Saleh A, Parmar H, Visram A, Muchtar E, Buadi F, Go R . Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2020; 20(9):596-601. PMC: 7484262. DOI: 10.1016/j.clml.2020.03.012. View

20.

Chen H, Zeng B, Zhao Y, Xie Y, Jin M . [Cytogenetic abnormalities and morphological changes of bone marrow in multiple myeloma: a pathological analysis of 151 cases]. Zhonghua Bing Li Xue Za Zhi. 2020; 49(11):1136-1141. DOI: 10.3760/cma.j.cn112151-20200306-00178. View